natgillin/translations-raw huggingface dataset:
In vitro release of the active ingredient from the preparation was determined in a paddle stirrer apparatus in accordance with Pharm. Eur. 
Oslobađanje in-vitro djelatne tvari iz pripravka određeno je u spravi za miješanje s velikom lopaticom (Blattriihrerapparatur) prema Europskoj farmakopeji.
System according to anyone of claims 10 to 13, wherein the concentrator (C) is adapted to perform the operation of transmitting a start time and an end time to the remote meter (RM) requesting transmission of consumption related data from said start time to said end time. 
Sustav prema bilo kojem od patentnih zahtjeva 10 do 13, pri čemu je sabirnik (C) prilagođen za provođenje operacija prijenosa vremena početka i vremena završetka u daljinski brojač (RM) zahtijevajući prijenos podataka vezanih uz potrošnju od navedenog vremena početka do završetka.
The safety helmet or headpiece of claim 1, wherein the light source is configured to emit a light beam of any colour or mixture of colours to identify different individuals and to improve visibility or rescue under differing environmental conditions. 
Sigurnosna kaciga ili naglavni dio (10, 24, 42, 50) prema zahtjevu 1, naznačena time da je izvor svjetlosti (14, 20, 40, 52) konfiguriran da emitira svjetlosnu zraku bilo koje boje ili mješavinu boja za prepoznavanje različitih pojedinaca i za poboljšanje vidljivosti ili za spašavanje u različitim uvjetima okoline.
Toilet basket according to claim 7, wherein preparations differing from one another are stored in the more than one container. 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su u spremnicima (3a, 3b, 3c, 3d). pohranjeni pripravci koji se međusobno razlikuju.
The method according to claim 5, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Metoda u skladu s patentnim zahtjevom 5, pri čemu L1 informacija signaliziranja ima ID informaciju podatkovnog reza koja identificira podatkovni rez.
in part (d), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:119 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:118; 
(d) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 115i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 114;
a bit stream separating step in which the speech decoding device separates a bit stream that includes the encoded speech signal into an encoded bit stream and a linear prediction coefficients, the bit stream received from outside the speech decoding device; 
koraku osnovnog dekodiranja, u kojem naprava za dekodiranje govora dekodira struju bitova koja sadrži kodirani govorni signal kako bi se dobilo niskofrekventnu komponentu, gdje struja bitova dolazi izvan naprave za dekodiranje govora;
A pipe clamp as claimed in claim 2, wherein the divided closure further comprises a first locking element for locking the second tongue in the first cavity and a second locking element for locking the first tongue in the second cavity. 
Stezaljka za cijev prema Zahtjevu 2, gdje podijeljeni element za zatvaranje dalje sadrži elemente (49) za zabravljivanje radi zabravljivanja jezičaka (47) u šupljinama (48).
is independently phenyl substituted with 0-3 R6, or a heteroaryl substituted with 0-2 R6; wherein said heteroaryl is selected from: thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, A compound according to of any one of claims 1-4, wherein: ring B is independently selected from: and 
(R54 fenil supstituiran sa 0-3 R", ili heteroaril supstituiran sa 0-2 R'; gdje je navedeni heteroaril odabran od: tiazolila, piridinila, pirimidinila, pirazinila, HR P20180641 T1 Spoj u skladu sa bilo kojim od patentnih zahtjeva 1-4, gdje je: prsten B nezavisno odabran od:
No. 4,235,877. A further aspect of the invention is a vaccine kit for concomitant or sequential administration comprising two multi-valent immunogenic compositions for conferring protection in a host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae and Neisseria meningitidis . 
Cjepivni komplet za istodobnu ili uzastopnu primjenu, naznačen time što sadrži dva polivalentna imunogena pripravka za postizanje zaštite kod domačina protiv bolesti koje uzrokuju bakterije Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, te Haemophilus influenzae, gdje navedeni komplet sadrži prvi spremnik, koji sadrži: tetanusni toksoid (TT), t>&
A composition according to claim 8, wherein said buffering agent is selected from phosphate buffer, citrate buffer, glycine/hydrochloric acid buffer, and mixtures thereof. 
Smjesa prema patentnom zahtjevu 8, naznačena time što je navedeno sredstvo za puferiranje izabrano između fosfatnog pufera, citratnog pufera, pufera glicin/klorovodična kiselina i njihovih smjesa.
• the compound is not reduced by 5a-reductase; 
(iv) Sa-reduktaza ne reducira spoj;
At the end of the initial purification step, IL-2 will typically be in precipitated form, particularly if being purified from inclusion bodies, but will have been separated from cellular debris to give a IL-2-rich paste for subsequent treatment. 
Na kraju početnog stupnja pročišćavanja, IL-2 će tipično biti u istaloženom obliku, osobito ako je bio pročišćen iz inkluzijskih tijela, ali će se separirati iz staničnog debrisa da dade smjesu bogatu s IL-2 za narednu obradu.
The method according to any one of claims 1 to 13, wherein the recovered supernatant has a rA13 specific FRETS-VWF73 activity of: at least 800 mU/µg; 
obnavljanje barem dijela supernatanta kulture, pri čemu oporavljeni supernatant ima rVWF specifičnu kofaktorsku aktivnost ristocetina od najmanje 30 mU/µg rVWF.
A compound for use according to any one of claims 1 to 11 wherein the disorder is COPD. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze COPD.
wherein the piston protrudes from the supporting plate until it affects a downward stroke of the motor when the stem of the cutting head is to be lowered for the tool exchanging operation, and 
- < zaizbijanje iz ploče (22) dok ne počne utjecati na silazni udar motora (25) kada se držak (30) mora spustiti radi izmjene alata,
In one embodiment, X is —C(O)—NR9—NR10R11, which can be depicted as formula c: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je X -C(O)-NR'-NR"R"', i ima formulu c: ža 17.
Support structure for a fence 
POTPORNA STRUKTURA ZA OGRADU
The process according to claim 1 wherein said compound of formula III is present at an amount varying from about 0.5 to about 50 moles per mole of compound of formula II. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj formule III dolazi u rasponu količina od otprilike 0,5 do otprilike 50 mol/mol spoja formule II.
Another aspect of the present invention relates to a method for replicating, amplifying or sequencing a template DNA which comprises contacting said DNA with a reaction mixture comprising at least: the DNA polymerase chimera of the invention, a buffer, 
Metoda za repliciranje, amplifikaciju ili sekvenciranje predloška DNK koji sadrži spomenuti povezni DNK s reakcijskom smjesom koja sadrži najmanje: a) DNK polimerazu himera prema bilo kojem zahtjevu od 1 do 11, b) pufer, c) magnezijev klorid, d) početnicu, i nukleozidne trifosfate.
Ingredients include guar gum, disaccharides and hexahydric saturated aliphatic alcohols. 
Sastojci obuhvaćaju guar gumu, disaharide i heksahidridne zasićene alifatične alkohole.
a VH region as depicted in SEQ ID NO: 387, and a VL region as depicted in SEQ ID NO: 388; 
387, i VL regiju kao što je prikazano u SEQ ID NO:
a first electrode; a second electrode; and, disposed between the first and second electrodes: (a) said perovskite; 
(i) prvu elektrodu; drugu elektrodu; a između prve i druge elektrode nalazi se: (a) navedeni perovskit;
In a particularly suitable embodiment, 3 or more depots are made along a single longitudinal position of the colon or rectum, preferably at positions 10, 2, and 6 o'clock of the cross-sectional axis of the colon or rectum. 
U jednom naročito prikladnom ostvarenju rade se 3 ili više odlaganja duž samo jednog uzdužnog položaja debelog crijeva ili rektuma, poželjno na položajima koji odgovaraju položaju male kazaljke na satu u 10 sati, 2 sata i 6 sati u poprečnom presjeku na os debelog crijeva ili rektuma.
oxidizing the compound of Formula XXVIII to give a compound of Formula XXIX; 
Formula XXII b. skidanje zaštite sa spoja Formule XXVII, čime se dobiva spoj Formule XXVIII:
a fluid conduit containing a heat transport fluid in thermal communication with the at least one heat exchanger where the heat transport fluid comprises a liquid phase and a gas phase within the fluid conduit, and is arranged for passive flow within the fluid conduit; 
fluidni cjevovod (214; 264) koji obuhvaća fluid za prijenos topline u termalnoj komunikaciji s najmanje jednim izmjenjivačem topline; najmanje jedan uređaj za prisilno toplinsko strujanje (221; 271), koji radi selektivno u svrhu pojačanja prijenosa topline u obliku toplinskog strujanja, u odnosu na najmanje jedan izmjenjivač topline; i upravljač koji je uređen za sljedeće:
The preparation is finally prepared in the form of tablets. 
Pripravak se konačno priređuje u obliku tableta.
A further aspect of the invention relates to a marker vaccine as described herein for use as a medicament in the prophylactic treatment (vaccination), preferably via intramuscular injection or oral application, of classical swine fever. 
15. Marker cjepivo u skladu s bilo kojim od patentnih zahtjeva 1 do 11 za uporabu kao lijek u zaštitnom liječenju (cijepljenju) klasične svinjske groznice, poželjno putem intramuskularne injekcije ili oralnom primjenom.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
if ring A in DB2 is a 6-membered aromatic ring, then substituents on ring B are not joined to form a ring fused to ring B; 
ako je prsten A u DB2 6-eročlani aromatski prsten, supstituenti na prstenu B nisu povezani kako bi tvorili prsten kondenziran s prstenom B;
and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 4), or a pharmaceutically acceptable salt thereof. 
i C-terminalna aminokiselina je amidirana kao C-terminalni primarni amid (SEQ ID NO: 4), ili njegova farmaceutski prihvatljiva sol.
The concentration of said carbonates and/or hydrogen carbonates may according to an aspect of the invention be at least 0.5% by weight, such as at least 1% by weight, and preferably at least 2% by weight, such as at least 3% by weight, and more preferably at least 4% by weight, such as at least 5% by weight. 
Metoda u skladu s patentnim zahtjevom 37, pri čemu je koncentracija navedenih karbonata i/ili hidrogen karbonata najmanje 0,5 % prema težini, kao što je najmanje 1% prema težini, a poželjno najmanje 2 % prema težini, kao što je najmanje 3 % prema težini, a još poželjnije najmanje 4 % prema težini, kao što je najmanje 5 % prema težini.
Also here, the curing takes place by means of the wood humidity and/or other polar groups being contained in the wood. 
Također i ovdje se lijepljenje odvija uz pomoć vlage iz drva i/ili iz drugih polarnih skupina koje su sadržane u drvu.
The facility of claim 1, further comprising a sand filter and a reverse osmosis system for processing water provided by said aerobic stirred reactor. 
Postrojenje prema bilo kojem od zahtjeva 1 do 4, nadalje sadrži pijesak-filter za obradu vode isporučene od strane SBR-a, i sustav reverzne osmoze za obradu vode isporučene od strane SBR-a.
the rigid auxiliary tube (7) is gradually introduced into the annular zone (4) by placing the necessary number of sections end to end so that its lower end is positioned at a distance in the range 50 cm to 100 cm with respect to the bottom of the annular zone (4); 
kruta pomoćna cijev (7) se postupno uvodi u prstenastu zonu (4) postavljanjem potrebnog broja dijelova od kraja do kraja tako da je donji kraj smješten na udaljenosti u rasponu od 50 cm do 100 cm u odnosu na dno prstenaste zone (4),
an external skin to insulate contents of said internal chamber; 
- vanjski pokrov (11) za izoliranje sadržaja navedene unutarnje komore;
contacting the trans-(+)-A9-tetrahydrocannabinol from step (b) with trans-(−)-A9-tetrahydrocannabinol and a non-polar organic solvent to form the first composition. 
(c) kontaktiranje trans-(+)-A'-tetrahidrokanabinola iz koraka (b) sa trans-(-)-A'-tetrahidrokanabinolom i nepolarnim organskim otapalom tako da formiraju prvi sastav.
The treated-group (n=9) receiving for additional 30 days 1.9 mg/kg/day of compound 12 (maintaining the 1% cholesterol in its diet), and the non-treated group (n=7) receiving a diet with a 1% of cholesterol for additional 30 days. 
Liječena skupina (n=9) primala je dodatnih 30 dana po 1,9 mg/kg/dnevno spoja 12 (održavanje 1% kolesterola u njihovoj dijeti), a neliječena skupina (n=7) je primala dijetu s 1% kolesterola još 30 dana.
reducing the above compound of formula XIa to obtain a compound of formula Va in the form of diastereoisomeric mixture (S,R+R,R) and, if desired, separating the compound of formula Va (R,S+S,S) into the single diastereomer Va (R,S) and the single diastereomer Va (S,S). It is another object of the present invention a process for preparing l-NBV of formula 
X) redukciju navednog spoja formule Xla, da bi se dobio spoj formule Va prema zahtjevu 1 u obliku dijasteroizomerne smjese (S, R+R, R) i, po želji, odvajanje smjese formule Va (S, R+R, R) na zaseban 15 dijasteromer Va (S, R) i zaseban dijasteromer Va (R, R).
further comprising sequencing the DNA from the bodily fluid of pregnant individual with a nucleic acid sequencer under conditions that produce DNA segment sequences containing the polymorphism sequences; 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži sekvenciranje DNK iz tjelesne tekućine trudne osobe upotrebom sekvencera nukleinskih kiselina pod uvjetima koji proizvode sekvence DNK segmenata u kojima je prisutan polimorfizam sekvenci.
The compound or salt for use according to claim 1, wherein said cancer is Sezary syndrome. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedena bolest rak dojke.
The pocket spring mattress of claim 13, wherein said strip of fabric further comprises at least one longitudinal connecting line extending parallel to the longitudinal direction of the string, which define said pockets together with the plurality of transverse connecting lines extending transversely to the longitudinal direction of the string. 
Madrac s ušivenim oprugama (1) iz Zahtjeva 13, pri čemu navedena traka tkanine nadalje sadrži barem jednu longitudinalnu poveznicu (32) koja se pruža paralelno longitudinalnom smjeru niza (3), koja definira navedene džepove skupa s više transverzalnih poveznica (33) koje se pružaju transverzalno longitudinalnom smjeru opruge
The method of claim 1, wherein the cumulative total amount of asparagine per unit volume in said medium is greater than approximately 8 mM. 
Postupak prema Zahtjevu 1, što je kumulativna ukupna količina asparagina po jedinici volumena u spomenutom mediju veća od približno 8 mM.
Use according to Claim 19 for the treatment or prevention of allergic rhinitis. 
Uporaba prema patentnom zahtjevu 19 za liječenje ili prevenciju alergijskog rinitisa.
Feed supplement, comprising 
Dodatak prehrani, koji sadrži
After 1 hr, HPLC revealed the reaction to be 90% complete. 
Poslije 1 sata, HPLC je otkrila da je reakcija 90% završena.
A process as in Claim 1, Claim 2 or Claim 3, wherein the alkyl lithium is (trimethylsilyl)methyl lithium and wherein the alkyl lithium is present in an amount in the range of from 2.0 to 2.5 molar equivalents. 
Postupak prema zahtjevu 1, zahtjevu 2 ili zahtjevu 3, naznačen time da alkillitij je (trimetilsilil)metil litij i pri čemu je alkil litij u količini u rasponu od 2,0 do 2,5 molarna ekvivalenta.
Then the extraction module surrounding the capsule is tightly closed, water is injected at the first face of the capsule, the beverage is produced in the volume of the capsule and a produced beverage can be drained from a second face of the capsule. 
Tada se ekstrakcijski modul koji okružuje čahuru čvrsto zatvori, voda se injektira na prvoj plohi čahure, proizvede se napitak u prostoru čahure i proizvedeni napitak može biti odveden na drugoj plohi čahure.
The coupling reaction is carried out in the presence of one or more 2,6-substituted pyridine compounds, for example, 2,6-lutidine, and a coupling reagent, for example, the hydrochloride salt of (ethyl[(3-dimethylamino)propyl]carbodiimide) (Formula Ia1). 
Formula ib u prisutnosti etil [(3-dimetilamino) propil|karbodiimid-klorovodika (EDCI-HC]), 2,6-lutidina, 1 otapala koje je prikladno omogućiti uvjete za dobivanje reakcijske smjese koja će sadržavati spojeni amidni produkt Formule Ica; Fonnula jea
The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration. 
Poželjno doziranje lijeka kojeg treba primijeniti vjerojatno će ovisiti o varijablama poput tipa i dosegu napredovanja bolesti ili poremećaja, ukupnom zdravstvenom stanju određenog pacijenta, relativnoj biološkoj djelotvornosti odabranog spoja, te o formulaciji pomoćne tvari, te o načinu primjene.
detecting a second phase relation between a wiring phase voltage at a said relay location and a wiring phase voltage at said remote location; and 
- < otkrivanje drugog faznog odnosa između faznog napona vodiča na spomenutoj relejnoj lokaciji i faznog napona vodiča na spomenutoj udaljenoj lokaciji;
at least 85% sequence identity, at least 95% sequence identity, at least 98% sequence identity, at least 99% sequence identity or 100% sequence identity to the amino acid sequence of SEQ ID NO:39; or no more than 15, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acid substitution(s) as compared to the amino acid sequence of SEQ ID NO:39 and/or no more than 5, 4, 3, 2 or 1 non-conservative amino acid substitution(s) as compared to the amino acid sequence of SEQ ID NO:39. 
(1) najmanje 85% identiteta sekvence, najmanje 95% identiteta sekvence, najmanje 98% identiteta sekvence, najmanje 99% identiteta sekvence ili 100% identiteta sekvence sa sekvencom aminokiseline SEK ID BR: 39; ili (1i) ne više od 15, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 ili 1 konzervativne supstitucije (a) aminokiseline u usporedbi sa sekvencom aminokiseline SEK ID BR: 39 i/ili ne više od 5, 4, 3, 2 ili 1 ne-konzervativne supstitucije (a) aminokiseline u usporedbi sa sekvencom aminokiseline SEK ID BR: 39.
The aqueous agrochemical suspension according to claim 1, wherein the suspension is a formulation and the amount of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole is within a range of 0.1 to 50 weight %, the amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 0.2 to 10 weight % and the amount of the inorganic thickener is within a range of 0.1 to 5 weight % and the amount of the dispersant is within a range of 1 to 15 weight %, as opposed to the total amount of the formulation. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1, gdje suspenzija je formulacija i količina 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola je u okviru opsega od 0.1 do 50 masenih %, količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 0.2 do 10 masenih % i količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 0.1 do 5 masenih % i količina dispergirajućeg sredstva je u okviru opsega od 1 do 15 masenih %, za razliku od ukupne količine formulacije.
A compound of the formula and stereoisomers and pharmaceutically acceptable salts thereof. 
Spoj, naznačen time, da ima formulu [image] i njegovi stereoizomeri te njegove farmaceutski prihvatljive soli.
The optoelectronic device as claimed in claim 8, wherein a first side and a second side of the channel provide the positive and negative poles of an electrical circuit, the first side and the second side being in electrical communication with the conductor material on the first channel face and the second channel face. 
Optoelektronički uređaj prema patentnom zahtjevu 8, naznačen time što prva strana i druga strana kanala (302) osiguravaju pozitivne i negativne polove električnog kruga, gdje su prve i druge strane s u električnoj komunikaciji s vodičkim materijalom (318) na prvim i drugim prednjim stranama kanala (302).
The protective wrapping according to claim 1, wherein the plastic film sheet comprises a melt adhesive arranged along the width of the sheet at at least one of the inner and the outer face thereof, such that the wrapping can be fixed by means thereof when wrapped. 
Zaštitni omotač u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ovoj od plastičnog filma sadrži talinsko ljepilo raspoređeno po širini ovoja s njegove unutarnje i/ili vanjske strane, tako da se omotač može učvrstiti uz pomoć istog kada je umotan.
Method according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity does not change by more than 10 %, preferably does not change by more than 6 %, and more preferably does not change by more than 3 %. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da se nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti otopine ne mijenja za više od 10 %, poželjno se ne mijenja za više od 6 %, poželjnije se ne mijenja za više od 3 %.
An isolated IL-23p19 antibody, comprising a light chain variable region amino acid sequence encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOS: 136-138 and 142-144. 
Izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1, naznačeno time da sadrži varijabilnu regiju lakog lanca aminokiselinske sekvence kodirane od strane nukleotidne sekvence izabrane od grupe koja se sastoji od SEQ ID NOS:142-144.
with pure water) prior to the assay to bring them within the range of a standard curve e.g. 
čistom vodom) prije analize da ih se dovede unutar opsega standardne krivulje, na pr.
The coextrusion die of claim 19, wherein the layer sequence repeater module comprises at least twenty of the spreader disks and at least twenty of the repeater disks. 
Kalup za suekstrudiranje u skladu s patentnim zahtjevom 19, naznačen time što modul za ponavljanje niza slojeva sadrži najmanje dvadeset razmačnih diskova (38) i najmanje dvadeset ponavljačkih diskova (40).
Number of cells karyotyped 
Broj međunarodne prijave:
The method according to claim 16, wherein moving the plant along the cutting devices comprises moving the plant upward and downward in a longitudinal direction of the support surface. 
Postupak prema bilo kojem od patentnih zahtjeva 11-13, naznačen time što se pomicanje biljke uzduž reznih uređaja sastoji od pomicanja biljke prema gore i dolje u uzdužnom smjeru nosive površine.